Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Imatinib mesylate is a small molecule drug that in vitro inhibits the Abelson (Abl), Arg (abl-related gene), stem cell factor receptor (Kit), and platelet-derived growth factor receptor A and B (PDGFRA and PDGFRB) tyrosine kinases. The drug has acquired therapeutic relevance because of similar inhibitory activity against certain activating mutations of these molecular targets. The archetypical disease in this regard is chronic myeloid leukemia, where abl is constitutively activated by fusion with the bcr gene (bcr/abl). Similarly, the drug has now been shown to display equally impressive therapeutic activity in eosinophilia-associated chronic myeloproliferative disorders that are characterized by activating mutations of either the PDGFRB or the PDGFRA gene. The former usually results from translocations involving chromosome 5q31-33, and the latter usually results from an interstitial deletion involving chromosome 4q12 (FIP1L1-PDGFRA). In contrast, imatinib is ineffective, in vitro and in vivo, against the mastocytosis-associated c-kit D816V mutation. However, wild-type and other c-kit mutations might be vulnerable to the drug, as has been the case in gastrointestinal stomal cell tumors. Imatinib is considered investigational for the treatment of hematologic malignancies without a defined molecular drug target, such as polycythemia vera, myelofibrosis with myeloid metaplasia, and acute myeloid leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Jousset, C., Carron, C., Boureux, A., Quang, C. T., Oury, C., Dusanter‐Fourt, I., Charon, M., Levin, J., Bernard, O., & Ghysdael, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.1.69 · Cited by 207
Cited by
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
Imatinib: A Breakthrough of Targeted Therapy in Cancer
Iqbal, N., & Iqbal, N. (2014) · Chemotherapy Research and Practice · doi:10.1155/2014/357027 · Cited by 470
Mapping normal and cancer cell signalling networks: towards single-cell proteomics
Irish, J. M., Kotecha, N., & Nolan, G. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1804 · Cited by 316
Piccaluga, P. P., Agostinelli, C., Califano, A., Rossi, M., Basso, K., Zupo, S., Went, P., Klein, U., Zinzani, P. L., Baccarani, M., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26833 · Cited by 303
Eosinophilia: secondary, clonal and idiopathic
Tefferi, A., Patnaik, M. M., & Pardanani, A. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06038.x · Cited by 298
Self-citation
Metadata
- Authors
- Pardanani, A., & Tefferi, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-10-01
- Volume
- 104
- Issue
- 7
- Pages
- 1931-1939
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1966470965
- Cited by
- 129
- References
- 3
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. https://app.cochat.ai/papers/10.1182/blood-2004-01-0246
- The paper
- Pardanani, A., & Tefferi, A. (2004). Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. https://doi.org/10.1182/blood-2004-01-0246
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.